Arix Bioscience PLC has released its unaudited estimated Net Asset Value (NAV) for October 2023. The company's total NAV for the month was £51.7 million, with a breakdown of £67.8 million in listed portfolio, £106.1 million in unlisted portfolio, £2.9 million in cash, and £228.5 million in other interests. The NAV per share was £1.77. Arix Bioscience is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies. They collaborate with entrepreneurs and provide capital, expertise, and global networks to accelerate the development of new treatments in the life sciences sector.